ISRCTN12835467招募中3 期
Prospective, single center study on radium-223 dichloride in patients with castration-resistant prostate cancer
Ospedale Civile Spirito Santo0 个研究点目标入组 25 人开始时间: 2018年1月24日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- Male
入选标准
- •1. Patients with progressive mCRPC and castrate levels of testosterone (<50 ng/dl)
- •2. Chemonaive or postchemotherapy
- •3. Symptomatic bone metastases, treated with Radium 223
排除标准
- •1. Patient <18 year old
- •2. Patient asymptomatic
- •3. Patient with ECOG >3
- •4. Patients with exclusive visceral metastases
- •5. Patient with non castrated testosterone levels
- •6. Patient concomitant use of abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, mitoxantrone
研究者
相似试验
进行中（未招募）
1 期
A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational statusPatients with mCRPC with asymptomatic progression while on abiraterone acetate or enzalutamideMedDRA version: 19.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001888-36-ESMedica Scientia Innovation Research (MedSIR ARO)52
已完成
3 期
Radium-223 Dichloride Long-term Follow-up Programeoplasm Metastasis / Bone and BonesJPRN-jRCT2080224668Bayer Yakuhin, Ltd.
进行中（未招募）
1 期
Radium-223 & Enzalutamide metastatic prostate cancer studyEUCTR2013-004850-97-IECancer Trials Ireland44
终止
2 期
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast CancerBreast NeoplasmsNCT02258464Bayer99
已完成
不适用
The study of combination therapy with radium-223 and enzalutamide in Osaka City UniversityCastration-resistant prostate cancer with bone metastasesJPRN-UMIN000029422Osaka City University Graduate School of Medicine10